Female Sexual Function Index (FSFI)

The Female Sexual Function Index, usually called the FSFI, is a 19-item self-report questionnaire designed to measure sexual function across six distinct areas: desire, arousal, lubrication, orgasm, satisfaction, and pain. Developed in 2000 by Raymond Rosen and colleagues, it has become one of the most widely used tools in both clinical practice and research for identifying sexual difficulties in women. Its reach extends well beyond academic studies, though, showing up in drug approval trials, surgical outcome tracking, and routine screening in gynecology and oncology settings. The questionnaire’s influence is matched by ongoing debate about who it works well for and who it leaves out.

What the Questionnaire Actually Asks

The FSFI asks about sexual experiences over the previous four weeks. Each of the 19 questions falls into one of six domains, and each domain gets its own score. The desire domain covers how often you felt sexual desire and how strong it was. The arousal domain asks about the frequency and level of sexual excitement during activity. Lubrication items ask about vaginal moisture during sexual activity and whether it was maintained. The orgasm domain covers frequency and difficulty of reaching orgasm. Satisfaction captures how close to your partner you felt, how satisfied you were with sexual activity overall, and how satisfied you were with your sex life in general. The pain domain addresses discomfort during and after vaginal penetration.

Responses are scored on a scale, with higher numbers reflecting better function in that area. Individual domain scores are calculated and then weighted to produce a total FSFI score that can range from roughly 2 to 36. The original validation study tested the questionnaire in 131 women without sexual difficulties and 128 women diagnosed with sexual arousal disorder, spread across five research centers. Internal consistency was strong across all domains, and the instrument reliably distinguished between the two groups.

The Cutoff Score and What It Means

A total FSFI score of 26.55 is the widely used threshold for distinguishing between women with and without sexual dysfunction. That number comes from a cross-validation study that tested where the dividing line best separates the two groups. At that cutoff, roughly 88% of women without sexual dysfunction were correctly classified, and about 71% of women with dysfunction were correctly identified. Adding the lubrication domain score as a secondary criterion bumped the accuracy for identifying dysfunction-free women up to about 77%, with a small trade-off in sensitivity.

In practice, this means a score below 26.55 flags possible sexual dysfunction, but it is a screening threshold rather than a diagnosis. The score does not tell a clinician which specific disorder a woman has or why she is experiencing difficulty. It is a starting point for a conversation or a way to track changes over time, not a definitive label. Clinicians typically look at individual domain scores alongside the total, since a woman might score well overall but have a very low desire or pain subscore that deserves attention.

How It Performs Across Chronic Illness

One of the FSFI’s most common uses is measuring sexual function in women living with chronic diseases, where sexual difficulties are both common and frequently overlooked. A large study that measured sexual dysfunction rates across multiple chronic conditions found that after adjusting for age, dysfunction was significantly more frequent in sexually active women with conditions like cancer (58%), stroke (59%), venous thromboembolism (56%), depression (55%), anxiety (54%), and musculoskeletal disease (48%), compared to about 34% in healthy women.

Chronic fatigue, which cuts across many of these conditions, appears to be a meaningful factor in its own right. Research on women with chronic diseases found that fatigue showed a strong association with lower FSFI scores, poorer sexual quality of life, and reduced marital adjustment.

⁴

In breast cancer treatment specifically, the FSFI has shown excellent reliability, with internal consistency scores above 0.90 for the total score and for each individual domain.

⁵ This matters because cancer treatment can affect every domain the FSFI measures. Hormonal therapies reduce desire, chemotherapy can impair lubrication, surgery can introduce pain, and the psychological burden can dampen arousal and satisfaction. Having a validated instrument that reliably captures all of these changes in the same population gives researchers and clinicians a consistent way to track treatment side effects and evaluate interventions meant to address them.

Menopause and Its Effect on Scores

The menopause transition reliably lowers FSFI scores, but not uniformly across domains. Research on postmenopausal women found that the severity of urogenital symptoms like vaginal dryness and discomfort had the strongest link to lower total scores and to the lubrication, satisfaction, arousal, and orgasm domains specifically. Psychological symptoms of menopause, such as irritability and mood changes, also predicted lower arousal, orgasm, and satisfaction scores. Being younger, being employed, and living in a rural area were all associated with better sexual function after adjusting for confounders.

⁶

The Spanish version of the FSFI has been validated specifically in postmenopausal populations, confirming that the instrument reliably discriminates between postmenopausal women with and without sexual dysfunction in that language and cultural context.

⁷ This kind of population-specific validation is important because the menopausal transition changes the baseline: what counts as “normal” lubrication or pain levels shifts, and the questionnaire needs to still capture meaningful variation rather than just flagging everyone over 50.

Pregnancy and the Postpartum Drop

Pregnancy and the postpartum period present a unique challenge for measuring sexual function. A prospective study in Nicaragua tracked women from late pregnancy into the early postpartum months and found a dramatic shift. During pregnancy, average FSFI scores were above the clinical threshold at about 27.8, suggesting sexual function was largely preserved. After delivery, the average score plunged to about 16.6, and 100% of postpartum participants fell below the dysfunction cutoff. The steepest declines were in lubrication, arousal, and desire.

⁸

That 100% figure is striking, and it raises a fair question: does the questionnaire genuinely capture dysfunction in this population, or is it picking up normal postpartum changes and calling them pathological? A validation study focused on this question found that the six-domain structure held up well in both pregnant and postpartum samples, meaning the questionnaire is measuring the same constructs it measures in other groups. However, the total score model was not well supported in these populations. The researchers recommended using domain scores rather than the total score when assessing perinatal women, since the instrument is most informative for those with lower sexual function and less effective at distinguishing differences among women who are doing well.

⁹

Short Versions for Faster Screening

Nineteen questions is not a burden in a research study, but in a busy clinical setting where sexual health is just one item on a long appointment agenda, shorter tools are appealing. Several abbreviated versions of the FSFI exist. A six-item version (FSFI-6) has been validated in Brazilian middle-aged women, showing acceptable model fit and good reliability.

¹⁰ A Spanish short version showed good test-retest reliability and established a cutoff of 18 or below for flagging possible sexual disorders, with sensitivity around 81% and specificity around 73%.

¹¹

Item response analysis has also suggested that a nine-item version captures more information across the spectrum of sexual functioning than the six-item version, with better range and fewer floor or ceiling effects. Most of the items dropped from the full FSFI in these shortened forms are ones that ask about the frequency of events or experiences, while the items retained tend to focus on quality and intensity.

¹² The trade-off is precision: shorter versions are useful for quick screening and for research where sexual function is one variable among many, but for detailed clinical assessment or tracking treatment response domain by domain, the full FSFI is still the standard.

Cross-Cultural Adaptations

The FSFI was developed in English in the United States, but its use has spread worldwide. Cross-cultural adaptation is more involved than simple translation. The Spanish adaptation, for example, was tested for semantic, conceptual, idiomatic, and content equivalence before being validated with test-retest reliability, convergent validity, and discriminant validity testing. The adapted version showed high reliability across all domains and could distinguish between women with and without sexual dysfunction, with moderate to excellent responsiveness to change.

¹³

A Portuguese adaptation went through a five-step process: translation, back-translation, formal equivalence assessment, specialist review, and pre-testing with target populations.

¹⁴ These steps matter because sexual norms, comfort with disclosure, and even the language people use to describe sexual experiences vary considerably across cultures. A questionnaire that asks about “sexual excitement” may land differently in a culture where that concept is described in other terms or where acknowledging it to a healthcare provider carries different social weight. The broad consensus from validation studies is that the FSFI’s structure holds up well across languages and settings, though cutoff scores may need local calibration.

How It Compares to Other Questionnaires

The FSFI is far from the only questionnaire that measures female sexual function, but it consistently comes out near the top in head-to-head comparisons. A systematic review of patient-reported outcome measures for sexual function in women with endometriosis found that the FSFI and the Sexual Activity Questionnaire (SAQ) had the best measurement properties overall. The FSFI was considered more relevant for evaluating medical treatments, while the SAQ was better suited for assessing outcomes after surgery.

¹⁵

Much of the recent literature on sexual dysfunction in chronic illness and cancer relies on the FSFI as its primary measure, which makes cross-study comparisons easier but also means the field’s understanding of sexual dysfunction is shaped by the FSFI’s particular framing of what matters.

¹⁶ When most studies use the same tool, the tool’s blind spots become the field’s blind spots.

Use in Drug Trials

The FSFI shows up frequently in clinical trials for treatments targeting female sexual dysfunction, particularly for hypoactive sexual desire disorder (HSDD). Pooled data from trials of flibanserin, the first FDA-approved drug for premenopausal HSDD, used the FSFI desire domain as a co-primary endpoint. Women taking flibanserin saw significantly greater improvements in desire scores compared to placebo.

¹⁷ Beyond desire alone, flibanserin-treated women also showed significantly greater improvements in arousal, lubrication, orgasm, and satisfaction subdomains compared to placebo, in both premenopausal and postmenopausal groups.

¹⁸

The FSFI’s role in regulatory submissions means its structure has real-world consequences. If the questionnaire is better at measuring certain kinds of improvement (lubrication, pain reduction) than others (relational satisfaction, context-dependent desire), then drugs that improve the easily measured domains have a built-in advantage in approval trials. This is not a theoretical concern. It is one of the reasons critics have pushed for updates to the instrument.

Who the FSFI Was Not Designed For

The FSFI’s most significant limitation is one that was baked in from the start: it assumes respondents are sexually active and engaged in partnered, penetrative sex. Women who are not currently sexually active receive artificially low scores because questions about lubrication, orgasm, and pain during intercourse default to the lowest response option when there is nothing to report. A critical review published in the Journal of Sex Research flagged this problem directly, noting that the FSFI is inappropriate for individuals who are not currently sexually active.

¹⁹

The heteronormative framing is another well-documented issue. Qualitative research with sexual and gender minority individuals found that they perceived the FSFI as reflecting a heterosexual view of sexual function. Participants described the questionnaire as unnecessarily medicalizing sexuality, focusing narrowly on penile-vaginal intercourse, and framing sexual domains around “performance” in a way that felt male-oriented.

²⁰ For women who have sex with women, questions about pain during vaginal penetration or lubrication during intercourse may not map onto their actual sexual experiences, leading to scores that do not reflect their real-world function or satisfaction.

Researchers have proposed workarounds. Modified scoring of the FSFI that accounts for variation in sexual frequency and partner status has been shown to produce reliable and valid assessments for sexual minority women, particularly when the desire subscale is reported separately.

²¹

The Inclusive Sexual Function Index

Rather than patching the FSFI with scoring workarounds, a newer instrument called the Inclusive Sexual Function Index (ISFI) was developed by directly adapting the FSFI’s content to be relevant across more diverse populations. Validated in a racially diverse LGBTQIA+ sample, the 18-item ISFI retains the core dimensions of sexual function while removing assumptions about the type of sexual activity, the gender of partners, and the body parts involved. The validation established reliability and validity for the ISFI as a psychometrically sound alternative for clinical and research use in populations the original FSFI was not built to serve.

²²

Whether the ISFI eventually displaces the FSFI in mainstream research and practice is an open question. The FSFI has enormous inertia: decades of data, validated translations in dozens of languages, and a presence in regulatory submissions that creates a strong incentive to keep using it for comparability. Switching instruments means losing the ability to directly compare new findings with older ones, which is a real cost in longitudinal research and meta-analyses. For now, the two tools are likely to coexist, with the FSFI remaining dominant in contexts where continuity matters and the ISFI gaining ground in studies that prioritize inclusivity or that specifically recruit diverse populations.

How Partner Dynamics Show Up in the Scores

The FSFI measures individual sexual function, but sexual difficulties rarely exist in isolation. Research comparing women with sexual interest and arousal disorder to control women found that, as expected, affected women scored lower on the desire, arousal, lubrication, and satisfaction domains and reported more pain during intercourse. But the same study also examined partners and found consequences for them as well, including effects on their own sexual, relational, and psychological adjustment.

²³ This is a useful reminder that the FSFI captures one person’s experience within what is usually a two-person dynamic. A low score is clinically meaningful on its own, but understanding the full picture often means looking at the relationship context the score sits inside.

1
PubMed. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function ↩︎
2
PubMed. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores ↩︎
3
The Journal of Sexual Medicine. IMPACT OF PREVIOUS OR CHRONIC DISEASES ON SEXUAL FUNCTION IN WOMEN ↩︎
4
Sexuality and Disability. Sexual Health Outcomes in Women with Chronic Diseases: Sexual Dysfunction, Quality of Sexual Life and Marital Satisfaction ↩︎
5
PubMed Central. A psychometric evaluation of the Female Sexual Function Index in women treated for breast cancer ↩︎
6
PubMed Central. Female Sexual Function and Its Association with the Severity of Menopause-Related Symptoms ↩︎
7
PubMed. The female sexual function index: reliability and validity in Spanish postmenopausal women ↩︎
8
PubMed Central. Decline in Female Sexual Function From Late Pregnancy to Early Postpartum: A Prospective Longitudinal Study in Nicaragua ↩︎
9
PubMed. A Validation Study of the Female Sexual Function Index for Use in Pregnant and Postpartum Samples ↩︎
10
PubMed Central. Validation of the Six-item Female Sexual Function Index in Middle-Aged Brazilian Women ↩︎
11
PubMed Central. Development and validation of a short version of the Female Sexual Function Index in the Spanish population ↩︎
12
Springer Link / Springer Nature (Archives of Sexual Behavior). Female Sexual Function Index Short Version: A MsFLASH Item Response Analysis ↩︎
13
PubMed Central. The Female Sexual Function Index: Transculturally Adaptation and Psychometric Validation in Spanish Women ↩︎
14
PubMed. Cross-cultural adaptation of the Female Sexual Function Index ↩︎
15
PubMed. Study Identifies Best Questionnaires to Assess Sexual Function in Patients With Endometriosis ↩︎
16
PubMed Central. Sexual function in chronic illness and cancer perspectives of the patient, partner, and healthcare provider; innovations; and updates: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024) ↩︎
17
PubMed. Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials ↩︎
18
PubMed Central. Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder ↩︎
19
PubMed. Critical flaws in the Female Sexual Function Index and the international index of Erectile Function ↩︎
20
PubMed Central. Sexual and Gender Minority Persons’ Perception of the Female Sexual Function Index ↩︎
21
PubMed Central. Applying the Female Sexual Functioning Index to sexual minority women ↩︎
22
PubMed. The Inclusive Sexual Function Index (ISFI): Adaptation and Validation in a Sample Diverse Across Racial/Ethnic, Sexual, and Gender Identities ↩︎
23
PubMed. Partners Experience Consequences, Too: A Comparison of the Sexual, Relational, and Psychological Adjustment of Women with Sexual Interest/Arousal Disorder and Their Partners to Control Couples ↩︎